Download PDF
Exp Clin Endocrinol Diabetes 2004; 112(3): 127-130
DOI: 10.1055/s-2004-817820
Article

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Myelofibrosis Secondary to Hyperparathyroidism

B. Kumbasar1 , I. Taylan1 , R. Kazancioglu1 , M. Agan2 , M. Yenigun1 , F. Sar1
  • 1Haseki Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
  • 2Istanbul University, Istanbul Medical Faculty, Department of Pathology, Istanbul, Turkey
Further Information

Publication History

Received: April 7, 2003 First decision: July 7, 2003

Accepted: August 25, 2003

Publication Date:
30 March 2004 (online)

Also available at
    Permissions and Reprints

Abstract

We report on a young female who had presented with fatigue, bilateral knee pain and gait disturbance. Primary hyperparathyroidism was diagnosed together with splenomegaly and anemia. Bone marrow biopsy revealed myelofibrosis. A parathyroid adenoma was excised during surgical intervention. As early as three months after the operation, hematologic parameters improved along with bone markers without any other intervention. The control bone marrow biopsy demonstrated well marked regression in marrow fibrosis. Her spleen has also gradually decreased in size.

These findings indicate that her myelofibrosis was the result of primary hyperparathyroidism. Anemia associated with primary hyperparathyroidism may be due to bone marrow fibrosis.

Key words

Hyperparathyroidism - myelofibrosis - anemia

References

  • 1 Abarca J, Trigonis C, Hamberger B, Granberg P O. Anaemia in primary hyperparathyroidism - fantasy or reality.  Ann Chir Gynaecol. 1985;  74 74-76
    PubMedGoogle Scholar
  • 2 Abdelhadi M, Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism.  J Clin Endocrinol Metab. 1998;  83 3845-3851
    CrossrefPubMedGoogle Scholar
  • 3 Athens J W. Myelofibrosis. Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN Wintrobe's Clinical Hematology. 9th ed. Philadelphia; Lea & Febige 1993: 2018-2033
    Google Scholar
  • 4 Bilezikian J P. Primary hyperparathyroidism: when to observe and when to operate.  Endocrin Metab Clin North Am. 2000;  29 465-477
    PubMedGoogle Scholar
  • 5 Boxer M, Ellman L, Geller R, Wang C A. Anemia in primary hyperparathyroidism.  Arch Intern Med. 1977;  137 588-590
    CrossrefPubMedGoogle Scholar
  • 6 Bringhurst F R, Demay M B, Kronenberg H M. Hormones and disorders of mineral metabolism. Wilson JD, Foster DW, Kronenberg HM, Larsen PD Williams Textbook of Endocrinology. 9th ed. Philadelphia; WB Saunders Company 1998: 1155-1209
    Google Scholar
  • 7 Bruder J M, Guise T A, Mundy G R. Mineral metabolism. Felig P, Frohman LA Endocrinology & Metabolism. 4th ed. New York; McGraw-Hill Inc 2001: 1079-1177
    Google Scholar
  • 8 Deaconson T F, Wilson S D, Lemann J. The effect of parathyroidectomy on the recurrence of nephrolithiasis.  Surgery. 1987;  102 910-913
    PubMedGoogle Scholar
  • 9 Duarte M E, Carvalho E F, Cruz E A, Lucena S B, Andress D L. Cytokine accumulation in osteitis fibrosa of renal osteodystrophy.  Braz J Med Biol Res. 2002;  35 25-29
    PubMedGoogle Scholar
  • 10 Eigelberger M S, Clark O H. Surgical approaches to primary hyperparathyroidism.  Endocrinol Metab Clin North Am. 2000;  29 479-502
    CrossrefPubMedGoogle Scholar
  • 11 Erslev A J. Anemia of chronic disease. Beutler E, Lichtman MA, Coller BS, Kipps TJ, Selighson U Williams Hematology. 6th ed. New York; McGraw-Hill Inc 2001: 481-487
    Google Scholar
  • 12 Falko J M, Guy J T, Smith R E, Mazzaferri E L. Primary hyperparathyroidism and anemia.  Arch Intern Med. 1976;  136 887-889
    CrossrefPubMedGoogle Scholar
  • 13 Grey A, Mitnick M A, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - a clinical research center study.  J Clin Endocrinol Metab. 1996;  81 3450-3454
    CrossrefPubMedGoogle Scholar
  • 14 Irvin G L, Newell D J, Morgan S D. Parathyroid metabolism after operative treatment of hypercalcemic (primary) hyperparathyroidism.  Surgery. 1987;  102 898-902
    PubMedGoogle Scholar
  • 15 Kotzmann H, Abela C, Heindl J, Clodi M, Riedl M, Barnas U, Heinzl H, Niederle B, Geissler K, Waldhausl W, Luger A. Effect of successful parathyroidectomy on hematopoietic progenitor cells and parameters of red blood cells in patients with primary hyperparathyroidism.  Horm Metab Res. 1997;  29 387-392
    PubMedGoogle Scholar
  • 16 Lindenbaum J. An approach to the anemias. Bennet JC, Plum F Cecil Textbook of Medicine. 20th ed. Philadelphia; Saunders Company 1996: 823-831
    Google Scholar
  • 17 Mallette L E. Anemia in hypercalcemic hyperparathyroidism.  Arch Intern Med. 1977;  137 572-573
    CrossrefPubMedGoogle Scholar
  • 18 Massry S G. Parathyroid hormone as a uremic toxin. Massry SG, Glassock RJ Massry and Glassock's Textbook of Nephrology. 3rd ed. Baltimore; Williams & Wilkin 1995: 1270-1303
    Google Scholar
  • 19 Meytes D, Bogin E, Ma A, Dukes P P, Massry S G. Effect of parathyroid hormone on erythropoiesis.  J Clin Invest. 1981;  67 1263-1269
    PubMedGoogle Scholar
  • 20 National Institutes of Health . Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus development conference statement.  Ann Intern Med. 1991;  114 593-597
    PubMedGoogle Scholar
  • 21 Nomura S, Ogawa Y, Osawa G, Katagiri M, Harada T, Nagahana H. Myelofibrosis secondary to renal osteodystrophy.  Nephron. 1996;  72 683-687
    PubMedGoogle Scholar
  • 22 Potts J T. Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders. Fauci AS, Braunwald E, Isselbacher KJ, Wilson J, Martin JB, Kasper DL, Hauser SL, Longo DL Harrison's Principles of Internal Medicine. 14th ed. New York; McGraw-Hill Inc 1998: 2227-2247
    Google Scholar
  • 23 Rao D S, Shih M S, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.  N Engl J Med. 1993;  328 171-175
    CrossrefPubMedGoogle Scholar
  • 24 Silverberg S J, Locker F G, Bilezikian J P. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism.  J Clin Endocrinol Metab. 1996;  81 4007-4012
    CrossrefPubMedGoogle Scholar
  • 25 Silverberg S J, Gartenberg F, Jacobs T P, Shane E, Siris E, Staron R B, McMahon D J, Bilezikian J P. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism.  J Clin Endocrinol Metab. 1995;  80 729-734
    CrossrefPubMedGoogle Scholar
  • 26 Spiegel A M. The parathyroid glands, hypercalcemia, and hypocalcemia. Bennet JC, Plum F Cecil Textbook of Medicine. 20th ed. Philadelphia; Saunders Company 1996: 1365-1373
    Google Scholar
  • 27 Strewler G J. Medical approaches to primary hyperparathyroidism.  Endocrinol Metab Clin North Am. 2000;  29 523-539
    CrossrefPubMedGoogle Scholar
  • 28 Turken S A, Cafferty M, Silverberg S J, De La Cruz L, Cimino C, Lange D J, Lovelace R E, Bilezikian J P. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism.  Am J Med. 1989;  87 553-557
    PubMedGoogle Scholar
  • 29 Urena P, Eckardt K U, Sarfati E, Zingraff J, Zins B, Roullet J B, Roland E, Drueke T, Kurtz A. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy.  Nephron. 1991;  59 384-393
    PubMedGoogle Scholar
  • 30 Zingraff J, Drüeke T, Marie P, Man N K, Jungers P, Bordier P. Anemia and secondary hyperparathyroidism.  Arch Intern Med. 1978;  138 1650-1652
    CrossrefPubMedGoogle Scholar

Baki Kumbasar

Emlak Bankasi Konutlari

A2 blok daire. 18

34590 Bahçelievler · Istanbul

Turkey

Phone: + 905324113403

Fax: + 90 21 25 89 62 29

Email: abakikumbasar@yahoo.com

      >